Vanguard Group Inc. Sells 16,697 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Vanguard Group trimmed its position in IDEXX by 0.2%, selling 16,697 shares and leaving it with 9,945,328 shares—about 12.46% of the company valued at roughly $6.73 billion at quarter-end.
• Insider selling has been notable: Director Sophie V. Vandebroek and EVP Nimrata Hunt recently sold shares, and insiders disposed of 45,957 shares (≈$29.86 million) over the past 90 days, with insiders now owning 0.79% of the stock.
• Strong quarterly results and guidance: IDEXX beat Q results (EPS $3.08 vs. $2.93 consensus) with revenue up 14.3% year-over-year, set FY2026 EPS guidance of $14.29–$14.80, and carries a MarketBeat consensus rating of "Moderate Buy" with a $760 price target.

Vanguard Group Inc. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,945,328 shares of the company's stock after selling 16,697 shares during the period. Vanguard Group Inc. owned about 12.46% of IDEXX Laboratories worth $6,728,313,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IDXX. Empowered Funds LLC increased its position in shares of IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company's stock valued at $646,000 after purchasing an additional 95 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $265,000. Jump Financial LLC boosted its holdings in shares of IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company's stock worth $2,967,000 after buying an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC bought a new position in IDEXX Laboratories during the second quarter valued at about $164,000. Finally, Sei Investments Co. grew its position in IDEXX Laboratories by 218.7% during the second quarter. Sei Investments Co. now owns 120,587 shares of the company's stock valued at $64,678,000 after buying an additional 82,755 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nimrata Hunt sold 2,693 shares of the business's stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the sale, the executive vice president directly owned 19,899 shares in the company, valued at $13,163,984.46. The trade was a 11.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 45,957 shares of company stock worth $29,862,109 in the last 90 days. 0.79% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $565.93 on Monday. The stock has a market capitalization of $44.95 billion, a P/E ratio of 43.30, a P/E/G ratio of 3.44 and a beta of 1.72. IDEXX Laboratories, Inc. has a 52-week low of $427.70 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock's 50-day simple moving average is $594.81 and its 200 day simple moving average is $653.15.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business earned $2.53 earnings per share. The company's quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on IDXX shares. UBS Group lowered their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. BTIG Research reduced their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday. Piper Sandler lowered their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a report on Monday, February 9th. Finally, Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a research note on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $760.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.